Hepatologie [Hepatology]

Détails

ID Serval
serval:BIB_BCD8B72129A2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Hepatologie [Hepatology]
Périodique
Revue Médicale Suisse
Auteur(s)
Mondada D., Pache I., Leopold K., Thorens J., Moradpour D., Gonvers J. J.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
01/2006
Volume
2
Numéro
49
Pages
218-20, 223-6, 228-30
Notes
English Abstract Journal Article Review --- Old month value: Jan 18
Résumé
Therapy by pegylated interferon-alpha (PEG-IFN-alpha), lamivudine and adefovir have significantly improved treatment perspectives for patients with chronic hepatitis B. New nucleos(t)ide analogues should permit the development of more effective combination therapies. In autoimmune hepatitis, if there is no response or an intolerance to therapy with prednisone and imurek, administration of mycophenolate mofetil should be envisaged. Ursodeoxycholic acid (UDCA) therapy, at a dosage of 13-15 mg/ kg/day, remains the treatment of choice for primary biliary cirrhosis and should be administered at an early stage to improve patients' survival. In the treatment of nonalcoholic fatty liver disease, thiazolidinediones show considerable promise, but further clinical studies are required in order to prove their efficacity and safety.
Mots-clé
Antiviral Agents/*therapeutic use Clinical Trials Fatty Liver/*drug therapy Hepatitis B, Chronic/*drug therapy Hepatitis C, Chronic/*drug therapy Humans Liver Cirrhosis/complications/*drug therapy Prognosis
Pubmed
Création de la notice
25/01/2008 17:05
Dernière modification de la notice
03/03/2018 20:57
Données d'usage